Friend or foe? – Janus Langerhans cells in skin immunity and promising clinical application

Curr Opin Immunol. 2025 Jul 18;96:102615. doi: 10.1016/j.coi.2025.102615. Online ahead of print. ABSTRACT Langerhans cells (LCs), the professional antigen-presenting cells in the epidermis, serve as the first line of defense in the skin’s immune system. With advancements in detection technologies and the development of diverse animal models, LCs have been shown to exhibit heterogeneous origins, … Read more

Primary sclerosing cholangitis: what is new in the therapeutic landscape

Curr Opin Immunol. 2025 Jul 17;96:102613. doi: 10.1016/j.coi.2025.102613. Online ahead of print. ABSTRACT Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease affecting the intra- and extra-hepatic bile ducts, leading to progressive inflammation and fibrosis. Its pathogenesis is complex and involves genetic predisposition, environmental triggers, and their interaction through the gut-liver axis, mediated … Read more

Neuroimmune mechanisms of neuropsychiatric systemic lupus erythematosus

Curr Opin Immunol. 2025 Jul 18;96:102608. doi: 10.1016/j.coi.2025.102608. Online ahead of print. ABSTRACT In systemic lupus erythematosus (SLE), chronic autoimmunity and sustained inflammation can lead to the development of neuropsychiatric lupus (NPSLE) in up to 80% of patients. Elevated interferon-alpha (IFNα) is detected in serum and cerebrospinal fluid, making it a major focus in studies … Read more

Insights into platelet post-transfusional human leukocyte antigen I immunization

Curr Opin Immunol. 2025 Jul 16;96:102607. doi: 10.1016/j.coi.2025.102607. Online ahead of print. ABSTRACT Although human leukocyte antigen (HLA) class I alloimmunization is asymptomatic, it nevertheless introduces a degree of complexity in the context of transplantation or allogeneic transfusion. In practice, it is evidenced by the presence of anti-HLA-I alloantibodies in patient circulation, which can lead … Read more

HLA-B27 as a potential target for the cure of axial spondyloarthritis

Curr Opin Immunol. 2025 Jul 16;96:102611. doi: 10.1016/j.coi.2025.102611. Online ahead of print. ABSTRACT Axial spondyloarthritis (axSpA) manifests with inflammatory back pain and is diagnosed predominantly in subjects carrying the human leucocyte antigen (HLA)-B27 allele. While not diagnostic for the disease or a predictive biomarker in the general population, there is convincing data on the pathogenic … Read more

Metabolic regulation of the immune cell in psoriasis: mechanisms and interventions

Curr Opin Immunol. 2025 Jul 16;96:102614. doi: 10.1016/j.coi.2025.102614. Online ahead of print. ABSTRACT Psoriasis is increasingly recognized as a metabolically regulated inflammatory skin disease. Aberrant glycolysis, oxidative phosphorylation, lipid metabolism, and amino acid metabolism reshape T cell, dendritic cell, macrophage, and neutrophil responses, driving chronic inflammation. Keratinocyte-derived metabolites further amplify immune dysfunction, establishing a reciprocal … Read more

Can we cure autoimmune hepatitis?

Curr Opin Immunol. 2025 Jul 14;96:102609. doi: 10.1016/j.coi.2025.102609. Online ahead of print. ABSTRACT Autoimmune hepatitis (AIH) is an organ-specific autoimmune disorder mainly affecting females and characterized by seropositivity for autoantibodies, hypergammaglobulinemia, and histological evidence of interface hepatitis. Liver damage in AIH is perpetrated by multiple immune cell subsets, including B, T lymphocytes, and macrophages. Dysfunction … Read more

Mapping economic outcomes: how biosimilars enhance access to health systems in Latin America and the Caribbean

Curr Opin Immunol. 2025 Jul 10;96:102606. doi: 10.1016/j.coi.2025.102606. Online ahead of print. ABSTRACT Biological therapy has revolutionized the treatment landscape of complex and chronic conditions, including autoimmune diseases and cancer. However, their high costs have significantly limited patient access, particularly in low- and middle-income regions, such as Latin America and the Caribbean (LAC). As cost-effective … Read more

Moving beyond the Janus kinase signaling kinases in the pathogenesis and treatment of psoriasis and psoriatic arthritis

Curr Opin Immunol. 2025 Jul 7;95:102601. doi: 10.1016/j.coi.2025.102601. Online ahead of print. ABSTRACT Psoriatic disease encompasses psoriasis and psoriatic arthritis. It is a chronic, progressive condition and leads to irreversible joint destruction. Conventional treatments used are disease-modifying antirheumatic drugs and biologics. Janus kinase (JAK) signal transducers and activators of transcription (STAT) cell signaling protein inhibitors … Read more

Concept of dual immune inhibitors for the treatment of drug-resistant psoriatic disease

Curr Opin Immunol. 2025 Jul 7;95:102602. doi: 10.1016/j.coi.2025.102602. Online ahead of print. ABSTRACT Biologic therapies have significantly improved the management of immune-mediated conditions like psoriatic disease, enhancing the quality of life of patients. However, monotherapy is often insufficient, especially in cases of relapse, concomitant psoriatic arthritis, and involvement of difficult-to-treat areas: the scalp, palmoplantar areas, … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri 301 Moved Permanently

301 Moved Permanently


nginx/1.24.0 (Ubuntu)